On the stock market since 2015, it operates in the world of health and science. It has 85 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 63% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $1.3M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 78% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 126% a year on average.
Over the last 12 months, company executives reported 17 buys and 2 sells. Management buying with its own money is usually read as a good sign.
The stock trades 97% above the average analyst price target.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
On our five-subject report card, OPGN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: OPGN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.